AZ-SWED Trial: Azithromycin Does Not Improve Preschool Wheezing Outcomes

DOI: 10.1056/NEJMoa2516505 | PubMed: PMID 42149992
Preschool wheezing is one of the most common pediatric ED presentations, and reaching for azithromycin can be tempting. Rhinovirus is the virus most often detected in these episodes, but pathogenic bacteria are commonly found in the nasopharynx of affected children, and some earlier outpatient data suggested that early antibiotic therapy might blunt severity.
The AZ-SWED trial (Azithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department), published in the New England Journal of Medicine, tested this directly in the ED. The trial was stopped early for futility [1].
Study Design
Denninghoff et al enrolled 840 children aged 18-59 months presenting with moderate-to-severe wheezing across eight PECARN emergency departments. The age range was chosen to target preschool-aged children before a clear asthma diagnosis is typically established, the population in whom antibiotic benefit has been most often hypothesized and in whom practice variation is greatest. Children were randomized to either a 5-day course of azithromycin or a matching placebo, with all participants also receiving standard care at the treating clinician’s discretion, including bronchodilators and corticosteroids.
Because prior research raised the possibility that bacterial co-colonization might identify a subgroup most likely to benefit from antibiotics [2-5], the trial pre-specified separate analyses for children with and without detectable nasopharyngeal Streptococcus pneumoniae, Moraxella catarrhalis, or Haemophilus influenzae, the three organisms most commonly implicated in respiratory illness in this age group. This let the investigators test whether the bacteria-positive children benefit, rather than leaving it as a post hoc question.
The primary outcome was symptom severity over 5 days, measured using the Asthma Flare-up Diary for Young Children (ADYC), a validated 17-item caregiver-reported instrument in which each symptom is scored from 1 (best) to 7 (worst) [6]. Secondary outcomes included ED and hospital length of stay and return ED visits or hospitalizations within 72 hours [1].
Results
Azithromycin provided no clinical benefit over placebo, regardless of bacterial detection status.
ADYC symptom scores over 5 days were similar between groups in children with detectable nasopharyngeal bacteria (p = 0.70) and in those without (p = 0.69). There were no meaningful differences in length of stay or in return visits or hospitalizations.
Rhinovirus was the most commonly detected virus, identified in 72.5% of participants. Pathogenic bacteria were detected on nasopharyngeal swab in 62% of children overall. Azithromycin did clear nasopharyngeal bacteria more effectively than placebo (58.7% vs 11.4%), confirming that the drug was biologically active. That microbiologic effect, however, did not translate to clinical improvement on any outcome measured.
Clinical Implications
This is a large, ED-based randomized trial, and it argues against routine antibiotic use in preschool wheezing. Up to a quarter of children hospitalized for wheezing currently receive antibiotics, which likely reflects the same uncertainty the trial set out to address. The bacteria detected in the nasopharynx do not appear to drive the acute wheezing episode in these children, and treating them does not change how the children do.
The dissociation between bacterial clearance and clinical outcomes is itself informative. The fact that azithromycin reliably eradicated nasopharyngeal bacteria without any detectable clinical signal suggests that these organisms are bystanders rather than drivers of the acute episode, at least in most preschool wheezers. This has implications beyond this trial: it cautions against using bacterial detection alone as a rationale for antibiotic prescribing in this age group.
Bottom Line
Routine azithromycin has no role in the management of preschool wheezing, even in children with detectable nasopharyngeal bacteria. Bronchodilators and corticosteroids where appropriate remain the mainstays of care, and these data give clinicians another reason to hold antibiotics in this group.
References
- Denninghoff KR, Casper TC, Zorc JJ, et al. Azithromycin for Preschoolers with Wheezing in the Emergency Department. N Engl J Med. Published online May 18, 2026. PMID: 42149992. doi:10.1056/NEJMoa2516505
- Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357(15):1487-1495. PMID: 17928596. doi:10.1056/NEJMoa052632
- Bacharier LB, Guilbert TW, Mauger DT, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA. 2015;314(19):2034-2044. PMID: 26575060. doi:10.1001/jama.2015.13896
- Stokholm J, Chawes BL, Vissing NH, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(1):19-26. PMID: 26704020. doi:10.1016/S2213-2600(15)00500-7
- Mandhane PJ, Paredes Zambrano de Silbernagel P, Aung YN, et al. Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial. PLoS One. 2017;12(8):e0182411. PMID: 28771627. doi:10.1371/journal.pone.0182411
- Ducharme FM, Jensen ME, Mendelson MJ, et al. Asthma Flare-up Diary for Young Children to monitor the severity of exacerbations. J Allergy Clin Immunol. 2016;137(3):744-749.e6. PMID: 26341275. doi:10.1016/j.jaci.2015.07.028















